SRC
TYRA icon

Samson Rock Capital’s Tyra Biosciences TYRA Stock Holding History

Samson Rock Capital’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,267
Closed -$269K – 62
2021
Q3 		$269K Buy
+15,267
New +$292K 0.17% 49

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Samson Rock Capital's TYRA Position: Q4 2021 in Review

Samson Rock Capital sold out of Tyra Biosciences (TYRA) in Q4 2021, closing a stake of 15,267 shares — an estimated $269K sold.

Samson Rock Capital first reported a position in TYRA in Q3 2021 and held it in 1 quarter. The position peaked at $269K in Q3 2021. 45 funds tracked by Wall St. Rank hold TYRA as of Q4 2021.

  • Samson Rock Capital reported no remaining Tyra Biosciences position as of Q4 2021 after selling out during the quarter.
  • Samson Rock Capital sold 15,267 Tyra Biosciences shares in Q4 2021, an estimated $269K.
  • Samson Rock Capital first reported a position in Tyra Biosciences in Q3 2021 and held it in 1 quarter.
  • Samson Rock Capital's Tyra Biosciences position peaked at $269K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2021.

Based on Samson Rock Capital's 13F filing for Q4 2021, filed 8 Feb 2022.